Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.57 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.57 |
| ▸ | PGR | P06401 | 1/20 | 0.57 |
| ▸ | AR | P10275 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.54 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.52 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.52 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.52 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.52 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.52 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.52 |
| ▸ | SHBG | P04278 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6445626 | 0.94 | CYP3A4 (0.58) | CYP3A4LMNAMAPTNR1I2CYP2C19 | |
| SCHEMBL6447931 | 0.94 | CYP3A4 (0.58) | CYP3A4LMNAMAPTNR1I2CYP2C19 | |
| SCHEMBL6446010 | 0.94 | CYP3A4 (0.56) | CYP3A4LMNAMAPTNR1I2CYP2C19 | |
| SCHEMBL6446961 | 0.94 | CYP3A4 (0.56) | CYP3A4LMNAMAPTNR1I2CYP2C19 | |
| SCHEMBL6442029 | 0.90 | SHBG (0.61) | CYP3A4LMNAMAPTNR1I2CYP2C19 | |
| SCHEMBL6443719 | 0.90 | SHBG (0.61) | CYP3A4LMNAMAPTNR1I2CYP2C19 | |
| SCHEMBL6439351 | 0.90 | SHBG (0.61) | CYP3A4LMNAMAPTNR1I2CYP2C19 | |
| SCHEMBL6442531 | 0.88 | CYP3A4 (0.52) | CYP3A4LMNAMAPTNR1I2CYP2C19 | |
| SCHEMBL6442628 | 0.88 | CYP3A4 (0.52) | CYP3A4LMNAMAPTNR1I2CYP2C19 | |
| SCHEMBL6444105 | 0.87 | CYP3A4 (0.55) | CYP3A4LMNAMAPTNR1I2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060024341-A1 | Microemulsion composition and related method | BIOTEST LABORATORIES, LLC | 2006-02-02 | — | — | US | claimed |
| US-20030134828-A1 | Composition and method for increasing in vivo androgen concentration | ROBERTS WILLIAM J (US) | 2003-07-17 | — | — | US | claimed |
| US-20030134831-A1 | Bioavailable prodrugs of androgenic steroids and related method | BIOTEST LABORATORIES, LLC | 2003-07-17 | — | — | US | claimed |
| US-20060024341-A1 | Microemulsion composition and related method | BIOTEST LABORATORIES, LLC | 2006-02-02 | — | — | US | disclosed |
| US-20050113354-A1 | Bioavailable prodrugs of androgenic steroids and related method | ROBERTS WILLIAM J (US) | 2005-05-26 | — | — | US | disclosed |
| US-6740646-B2 | Bioavailable prodrugs of androgenic steroids and related method | BIOTEST LABORATORIES, LLC | 2004-05-25 | — | — | US | disclosed |
| US-20030134830-A1 | Bioavailable prodrugs of androgenic steroids and related method | BIOTEST LABORATORIES, LLC | 2003-07-17 | — | — | US | disclosed |
| US-20030134828-A1 | Composition and method for increasing in vivo androgen concentration | ROBERTS WILLIAM J (US) | 2003-07-17 | — | — | US | disclosed |
| US-20030134831-A1 | Bioavailable prodrugs of androgenic steroids and related method | BIOTEST LABORATORIES, LLC | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060024341-A1 | Microemulsion composition and related method | LIPA, SGMS1, SGMS2 | CYP3A4 1827/4885LMNA 957/4885MAPT 1902/4885 |
| US-20030134828-A1 | Composition and method for increasing in vivo androgen concentration | SHBG, CYP21A2, CYP19A1 | CYP3A4 340/4885LMNA 436/4885MAPT 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.